Evidence map›Paper›PMID 27766202›Full record

ReviewNeuroImage. Clinical2016

Pharmaco fMRI: Determining the functional anatomy of the effects of medication.

Britta Wandschneider, Matthias J Koepp

Open access · goldAbstract readReview
In one paragraph

Review in NeuroImage. Clinical, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Opioid-specific brain connectivity dynamics distinguish analgesia from secondary effects: Studies in male mice.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
  7. Emotion anticipation and processing in depression: Behavioral, neural, and physiological reactivity.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. The Role of fMRI in Drug Development: An Update.Advances in neurobiology · 2023
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Britta WandschneiderDepartment of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK; MRI Unit, Epilepsy Society, Chalfont St Peter, UK.
Matthias J KoeppDepartment of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK; MRI Unit, Epilepsy Society, Chalfont St Peter, UK.
University College London · GB

Funding

Department of Health
6 · The paper itself

Abstract

Functional MRI studies have helped to elucidate underlying mechanisms in complex neurological and neuropsychiatric disorders. Disease processes often involve complex large-scale network interactions, extending beyond the presumed main disease focus. Given both the complexity of the clinical phenotype and the underlying dysfunctional brain circuits, so called pharmaco-fMRI (ph-MRI) studies probe pharmacological effects on functional neuro-anatomy, and can help to determine early treatment response, mechanisms of drug efficacy and side effects, and potentially advance CNS drug development. In this review, we discuss recent ph-MRI research in three major neuropsychiatric and neurological disorders and associated network alterations, namely selective serotonin and noradrenergic reuptake inhibitors in affective disorders and emotional processing circuits; antiepileptic drugs in epilepsy and cognitive networks; and stimulants in attention-deficit/hyperactivity disorder and networks of attention control. We conclude that ph-MRI studies show consistent and reproducible changes on disease relevant networks, and prove sensitive to early pharmacological effects on functional anatomy associated with disease. Further CNS drug research and development would benefit greatly from improved disease phenotyping, or biomarkers, using advanced imaging techniques.

Indexed as

Attention Deficit Disorder with HyperactivityEpilepsyMood DisordersNerve NetAnticonvulsantsCentral Nervous System StimulantsHumansMagnetic Resonance ImagingNeuropharmacologySerotonin and Noradrenaline Reuptake InhibitorsAnticonvulsantsCentral Nervous System StimulantsSerotonin and Noradrenaline Reuptake InhibitorsACC, anterior cingulate cortexADHD, attention-deficit/hyperactivity disorderAED, antiepileptic drugsBiomarkerBOLD, blood oxygen level-dependent signalCBZ, carbamazepineCNS, central nervous systemCNS drug researchDAT, dopamine transporterFunctional MRIJME, juvenile myoclonic epilepsyLEV, levetiracetamLTG, lamotrigineNaRI, noradrenergic reuptake inhibitorsNeuroimagingOXC, oxcarbazepinePharmacologicalPh-MRI, pharmacological functional MRISSRI, selective serotonin reuptake inhibitorsTLE, temporal lobe epilepsyTMS, transcranial magnetic stimulationTPM, topiramateVPA, valproateZNS, zonisamide

Identifiers

PMID27766202
PMCPMC5067101
OpenAlexW2527978353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.